ANDA 208639, held by Apotex. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 208639 (Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate), held by Apotex, was first approved by FDA on Mar 21, 2018, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 21, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Feb 17, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 21, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters